Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a
non-executive board director.
With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical
company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business.
During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to
sustainable growth and profitability.
The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are
critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful
acquisition by Perrigo Company plc."
David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's
growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.
England's chief pharmaceutical officer (CPhO) David Webb has promised his "wholehearted support" for the community pharmacy sector at the board meeting of the National Pharmacy Association (NPA) on 28 June in St Albans.
After hearing the CPhO at the meeting, NPA chair, Andrew Lane, later declared: "David is someone we can do business with."
Webb thus listed his priorities as head of profession: integration of independent prescribing as part of pharmacy practice by 2026; promotion of inclusive pharmacy
practice for all pharmacy professionals; assurance of post-registration practice; developing the role of pharmacy technicians; support for Integrated Care Systems
and Primary Care Network pharmacy teams (including community pharmacy); medicines optimisation; and strengthening of professional leadership for community pharmacy.
He also reported that NHS England had recently increased its team of regional pharmacy integration leads from seven to 14, creating seven new senior posts.
Webb told NPA board members: "I want sincerely to thank community pharmacy teams for everything they are doing and to say that you have my wholehearted support. I believe in the importance of community pharmacy and will listen and engage as I've already demonstrated.
The Association of Independent Multiple Pharmacies (AIMp) has appointed David Vanns as its non-executive Chairman following the retirement of its long serving
Chair Peter Cattee. Vanns will take up the role from April 2023.
Cattee, one of the co-founders of AIMp took up the role as its Chairman in 2000. He is also a non-CCA representative on the PSNC. Despite retiring as chairman Cattee
will remain on the AIMp board.
Commenting on his retirement Cattee said: "It's been my great good fortune to work with almost all of the owners of pharmacy groups throughout England, Scotland and
Wales over the years and many other talented people throughout the sector. It's been during a period of increasing consolidation, something which our own business
has reflected, and the original founders and Board members Yakub Patel, Kirit Patel, Steve Williams and David Vanns have all been instrumental in shaping pharmacy
negotiations to better reflect the views of our natural constituency - pharmacy group owners.
A spokesperson for AIMp said: "We thank Peter for his services and dedication to AIMp throughout the years. Our organisation has grown to be a diverse and dynamic
organisation representing and supporting pharmacy groups of all sizes, small and large. Our main identity and what unites us in AIMp, irrespective of the size of
the pharmacy group, is being Independents, and we are very proud of our identity. We look forward to continuing our work in representing and supporting our members
in the best way possible."
In a delightful announcement, the University of Brighton has honoured NHS England's Chief Pharmaceutical Officer, David Webb with its prestigious Doctor
of Science honorary degree
Webb's award is a highlight of the university's graduation ceremony which celebrated the graduation of over 3,400 undergraduate and postgraduate students from 92
countries at the Brighton Centre this week.
The accolade recognises Webb's transformative work in the pharmacy services within the NHS, highlighting the profound impact his contributions have had on delivery
of healthcare across the UK.
Under Webb's leadership, significant advancements have been made in integrating pharmacy into NHS care pathways, improving patient outcomes, and enhancing the role
of pharmacists and pharmacy technicians in the healthcare system.
Webb expressed his honour stating, "I am delighted to receive the honorary award of Doctor of Science from the University of Brighton in recognition of both my
contribution to pharmacy in the NHS"
AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company.
In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing
strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations,
and trading.
Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the
industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."
HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer.
The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022.
David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of
over-the-counter self-care products.
He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to
step away from the business.
"I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including
ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned
to elevate this business and these brands to the next level."
England's chief pharmaceutical officer David Webb on Friday (July 22) officially opened a community health hub at a Hindu temple in west London.
The interactive health hub, which was built as part of the 'Festival of Inspiration' - a 10-day cultural celebration of the UK's South Asian Hindu communities, will
provide visitors with free health awareness and well-being advice.
The cultural extravaganza, which ends on July 31, draws upon the inspiring life, work and wisdom of His Holiness Pramukh Swami Maharaj, one of the world's great
spiritual leaders and creator of the iconic Neasden Temple.
Sharing his reflection on the festival and the health hub, Webb said: "It's been an absolute pleasure to visit and be a part of the Festival of Inspiration on the
hundredth centenary of His Holiness. I've been really impressed by the extensive programme of engagement with the community to improve health and wellbeing."
Senior pharmacist Prof Mahendra Patel accompanied Webb during the opening ceremony.
David Webb has been appointed as the new chief pharmaceutical officer (CPO) for England.
He will take over from Dr Keith Ridge who steps down next month after serving the role for sixteen year.
Webb is currently chief pharmacist and clinical director for pharmacy and medicines optimisation at Guy's and Thomas's NHS Foundation Trust, London.
Sharing the news of his appointment on Twitter on Friday afternoon (January 7), he said he was "really delighted and honoured" to be named the CPO for NHS England
and that he was as the appointed Chief Pharmaceutical officer for "looking forward to working with pharmacy leaders, colleagues & teams across all sectors from February."
He also extended his gratitude to the outgoing CPO for his "outstanding contribution" who, in turn, congratulated Webb and said it was "an honour to be handing over to him".
In the same message, Dr Ridge thanked "all the great people I've worked with over the last 16 years for your support, friendship, good humour, great ideas & challenge. I wish you all well for the future."
The National Pharmacy Association (NPA) has commissioned Professor David Taylor of University College London to investigate the implications of all-time high
inflation rates on community pharmacies in the UK.
Professor Taylor's will assess rates of inflation affecting community pharmacy across the UK, using public data sources whilst examining inflated costs in the
context of the current five year contractual framework in England (2019-2024).
He would review the EY (Ernst & Young) report into pharmacy funding, to identify whether current inflationary pressures could change any of the findings and
consider the policy implications and impacts of inflationary pressures, including pharmacy's ability to prepare for a more clinically focused future and maintain
current core services.
NPA chief executive Mark Lyonette said: "Inflationary pressures are eating into the limited funds provided by the NHS for pharmacy services. We believe the real
level of inflation for pharmacy businesses could be higher than the CPI inflation rate, which itself is at a 40 year high. Staff and locum costs in the sector as
well as medicines costs have risen dramatically.
With higher than usual number of cases of scarlet fever, caused by invasive Group A streptococci (iGAS) infections being reported in children across the
country, Chief Pharmaceutical Officer for England David Webb has assured pharmacies of sufficient supply of antibiotics.
In a letter, shared by the PDA, Webb also urged the pharmacies to order antibiotic stocks sensibly.
"Local pharmacy teams may be experiencing a temporary interruption of supply of some relevant antibiotics due to increased demand. On a national level, sufficient
stock exists for the NHS," he said.
He said NHS is working closely with the Department of Health and Social Care (DHSC) and has taken actions to help ensure medicines continue to be available.
He explained that the supplies of antibiotics for the treatment of Group A Strep, particularly phenoxymethylpenicillin presentations, have seen a surge in demand,
leading to potential constraints at certain wholesalers and pharmacies,
David Webb, the Chief Pharmaceutical Officer for England, acknowledged that the "pressure in the system is high", but urged everyone to "keep our eye on the
design" of the NHS plan, adding that the "the objective is to bring the different parts of primary care together" in the patient interest.
Speaking during the opening keynote session at the the National Pharmacy Association (NPA) conference held on Thursday (13 October), he added that the NHS plan
intends to bring different parts of primary care together to help patients.
He said the new integrated care boards (ICBs) are a key strategic framework as they provide the "potential to form partnerships to deliver integrated services across
larger populations".
"ICBs will want to work with Local Pharmaceutical Committees to plan for the local population and the new community pharmacy clinical leads in ICBs, who have been
funded by NHS England, are there to advise."
He explained that once an ICB takes over the commissioning of pharmaceutical services (which they are all due to do by April 2023), it could use its funds to
commission a local enhanced service as an add on to an advanced service. For instance, a CVD risk assessment could be added to the blood pressure check service.
The National Pharmacy Association (NPA) has announced that the Chief Pharmaceutical Officer for England, David Webb will be among the keynote speakers at the
Pharmacy Odyssey Conference on 13 October.
He and other special guests will discuss the future of community pharmacy within the NHS, during a day of insight and practical advice for pharmacy teams.
The NPA promises expert opinion on the current pressures in the sector and a thorough exploration of the long-term picture.
NPA Director of Membership, Simon Tebbutt, explains: "With the NPA centenary in 2021 behind us, this will be a foray into the future - mapping the coming decade,
and next half-century - as well as covering the many challenges of the present time."
The theme of the conference, to be held online and sponsored by Novo Nordisk, is Pharmacy Odyssey: Services, Supply and Sustainability.
Chair of the health and social care committee Steve Brine and England's chief pharmacist David Webb are among a raft of speakers who will be addressing
delegates at the 13th Annual Sigma Community Pharmacy Conference to be held in Punta Cana, Dominican Republic from Sunday (March 5).
Day I of the conference will also feature a Q&A session with PSNC CEO Janet Morrison and her lead negotiator Mike Dent, which will be presented as a live webinar
via YouTube for those unable to attend in person.
Sigma Pharmaceuticals has invited all interested community pharmacists and stakeholders in the UK to join the 90 minutes session by clicking this link.
Those joining the session will not only be able to listen to the Q&A session - which will run between 6.30PM and 8.00PM in UK on Sunday - but also ask questions to
the PSNC executives via a live YouTube chat.
Sigma says the operating landscape for community pharmacy has altered dramatically since it last held its 'away conference' in the Philippines in February 2020. The
role of the independents - post pandemic - has rapidly evolved and has now been recognised by the health secretary as playing a significant part in the health of
the nation.
In this article Dr. David Beran gives helpful advise to medical students for choosing which type of residency to pursue. The medical specialty decision is stressful-by thinking of the specialties in big buckets and asking major questions, you can narrow down your list...
The Association of Independent Multiple Pharmacies (AIMp) celebrated achievements of its members during the pandemic at its first annual 'ball and award' ceremony held last week in London.
To highlight the important role played by pharmacy teams, the association representing community pharmacy businesses with multiple branches, introduced two award categories - for patient safety and social care.
Stephen Walls from H I Weldricks won the Patient Safety Awards and Sandeep Dhami, Nadia Hussain and Sachin Basandrai from MW Phillips won the Social Care Award.
Congratulating the winners, Leyla Hannbeck, CEO of AIMp, said that community pharmacy teams "have worked tirelessly to deliver patient care throughout the pandemic." David McNicol, head of sales at AAH Pharmaceuticals, noted that the country and community pharmacy witnessed the toughest 18 months, and the gathering provided an opportunity to discuss ongoing challenges.
The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials.
The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients.
David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care.
"We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite
and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.
Britain on Monday (January 10) put the biggest private health companies on high alert to deliver crucial treatments such as cancer surgery should Omicron
overwhelm National Health Service hospitals in England.
The United Kingdom's death toll from the Covid-19 pandemic stands at 150,154, the world's seventh worst official Covid toll after the United States, Brazil, India, Russia, Mexico and Peru.
Prime minister Boris Johnson has bet on refraining from lockdowns to deal with the Omicron variant which in recent weeks has swept across the UK, albeit with death
rates significantly lower than previous waves.
In a sign of just how stretched the NHS could become, health secretary Sajid Javid ordered England's NHS to strike a three-month deal with private health companies to allow patients to get treatments such as cancer surgery outside.
"Millions of patients have already got their tests and treatment quicker thanks to our existing deal with independent providers," said David Sloman, NHS England chief operating officer and Covid incident director.
The National Pharmacy Association (NPA) has welcomed the Chancellor's commitment to increase the NHS budget, hoping that 'community pharmacies benefit from
this investment'.
The association is urging the government to address years of underfunding so that community pharmacies can avoid staff lay-offs to cover the increasing costs of the
national living wage.
The government's uplift of the National Living Wage was confirmed in its latest budget announcement to tackle the cost of living crisis. The NHS budget will also be
increased in each of the next two years by £3.3bn.
A recent NPA commissioned report by Professor David Taylor from University College London predicted that wage inflation and other cost pressures could combine with
funding cuts to lead to cut-backs and pharmacy closures.
AAH Pharmaceuticals Ltd (AAH) has exceeded the milestone of delivering over 70 million COVID-19 vaccination doses across England, since it was awarded a
contract in December 2020.
In addition, AAH has delivered over 100 million ancillary items to more than 3,000 healthcare providers.
David Bound, chief executive officer of AAH, said: "This is a huge milestone for AAH as we work tirelessly to support our communities. It's also a ringing
endorsement of our delivery drivers, warehouse operatives, and specialist logistics teams and the determination, dedication, and passion they continue to show
throughout this extraordinary period."
The vaccination programme was also recognized by the Supply Chain Excellence Awards.
Chris Emmott, senior project lead - Supply Chain, commented: "I'm incredibly proud that AAH was chosen for this job, particularly as we had the skills, the
experience, and a great team to help facilitate the needs of the country. To get ready for a project like this, everybody's worked very long hours, they've
worked weekends to get everything ready.